單株抗體療法市場規模、佔有率和成長分析（按生產方法、來源、治療方法、給藥方法、最終用戶和地區分類）—2026-2033年產業預測

預計到 2024 年，單株抗體療法市場規模將達到 1,653 億美元，到 2025 年將達到 1,773.6 億美元，到 2033 年將達到 3,116.4 億美元，預測期（2026-2033 年）的複合年成長率為 7.3%。

全球單株抗體療法市場的主要驅動力是癌症、自體免疫疾病和心血管疾病等慢性疾病發生率的不斷上升。單株抗體在應對這些健康挑戰方面的有效性使其在臨床實踐中廣泛應用。此外，人口老化和文明病相關健康問題的日益增加也持續推動著市場成長。技術進步使得高特異性和高效率抗體的研發成為可能，提升了其治療潛力。對個人化醫療和標靶治療策略的日益重視也是推動單株抗體療法需求的關鍵因素，使其成為現代醫療保健解決方案的重要組成部分。

單株抗體療法市場促進因素

生物技術和基因工程的進步極大地推動了單株抗體療法的發展。這些領域的創新使得人們能夠研發出特異性更高、療效更佳、副作用更小的抗體。基因工程技術的應用使研究人員能夠設計出有效針對特定疾病的單株抗體，從而拓展了其治療潛力。這項進步不僅拓寬了單株抗體療法的應用範圍，也提高了治療成功率，進而鞏固了這些療法在現代醫學中的地位。

限制單株抗體療法市場的因素

單株抗體療法雖然有益，但並非沒有挑戰，因為它們可能引起多種副作用和安全問題。患者在接受治療時可能會出現輸注相關反應，程度從輕微到嚴重不等。此外，還存在免疫抗原性風險，即免疫系統對治療產生不良反應。脫靶效應也可能發生，導致體內出現意想不到的相互作用。為了保障病人安全並維護對這些治療方法的信心，必須進行全面的監測，實施嚴格的安全評估，並清楚傳達潛在風險。有效管理這些問題對於確保患者健康和符合監管要求至關重要。

單株抗體療法市場趨勢

單株抗體療法市場正朝著個人化和標靶治療的引入和開發顯著成長的方向發展。這一趨勢的驅動力在於先進診斷技術、基因譜分析和生物標記識別的整合，使醫療服務提供者能夠為每位患者量身定做治療方案。這種策略性的個人化治療能夠提高療效並最大限度地減少副作用，有助於改善癌症、自體免疫疾病和感染疾病等疾病的整體治療效果。隨著醫療保健格局的演變，對符合個人化醫療原則的單株抗體的需求持續成長，推動著生物製藥產業的創新並重塑著治療模式。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球單株抗體療法市場規模（按產量和複合年成長率分類）（2026-2033 年）

• 體外
• In vivo

全球單株抗體療法市場規模（按來源和複合年成長率分類）（2026-2033 年）

• 人類來源
• 人性化
• 嵌合體體
• 其他

全球單株抗體療法市場規模（依療法分類）及複合年成長率（2026-2033 年）

• 自體免疫疾病與發炎性疾病
• 腫瘤學
• 血液學
• 眼科
• 其他

全球單株抗體療法市場規模（按給藥途徑和複合年成長率分類）（2026-2033 年）

• 靜脈注射
• 皮下注射
• 其他

全球單株抗體療法市場規模（按最終用戶分類）及複合年成長率（2026-2033 年）

• 醫院
• 長期照護機構
• 其他
• 全球單株抗體療法市場規模及複合年成長率（2026-2033）
• 北美（生產、供應來源、處理、管理、最終用戶）
  • 美國
  • 加拿大
• 歐洲（生產、來源、處理、管理、最終用戶）
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區（生產、來源、處理、管理、最終用戶）
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲（生產、來源、處理、管理、最終用戶）
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲（生產、供應來源、處理、管理、最終用戶）
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
• 2023-2025年營收年比比較

主要企業簡介

• Zoetis Inc.（USA）
• Merck & Co., Inc.（USA）
• Elanco Animal Health Incorporated（USA）
• Boehringer Ingelheim International GmbH（Germany）
• Ceva Sante Animale（France）
• Virbac（France）
• Vetoquinol（France）
• Bayer AG（Germany）
• Novartis AG（Switzerland）
• Eli Lilly and Company（USA）
• Sanofi（France）
• Intervet Inc.（Netherlands）
• Alltech（Ireland）
• Huvepharma（Bulgaria）
• Kemin Industries（USA）
• Novus International（USA）
• Biomin Holding GmbH（Austria）
• ADM Animal Nutrition（USA）
• Adisseo（France）
• DSM（Netherlands）

結論與建議

Monoclonal Antibody Therapy Market size was valued at USD 165.3 Billion in 2024 and is poised to grow from USD 177.36 Billion in 2025 to USD 311.64 Billion by 2033, growing at a CAGR of 7.3% during the forecast period (2026-2033).

The global monoclonal antibody therapy market is significantly driven by the rising incidence of chronic diseases, including cancer, autoimmune disorders, and cardiovascular issues. The effectiveness of monoclonal antibodies in addressing these health challenges has led to their increasing acceptance in clinical settings. Furthermore, an aging demographic alongside the escalation of lifestyle-related health concerns continues to bolster market growth. Advances in technology have facilitated the development of highly specific and effective antibodies, enhancing their therapeutic potential. The growing emphasis on personalized medicine and targeted treatment strategies is also a key factor propelling the demand for monoclonal antibody therapies, positioning them as a vital component in modern healthcare solutions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Monoclonal Antibody Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Monoclonal Antibody Therapy Market Segments Analysis

Global Monoclonal Antibody Therapy Market is segmented by production, source, therapy, administration, end user and region. Based on production, the market is segmented into in vitro and in vivo. Based on source, the market is segmented into human, humanized, chimeric and other. Based on therapy, the market is segmented into autoimmune and inflammatory disorders,oncology, hematology, ophthalmology and others. Based on administration, the market is segmented into intravenous, subcutaneous and other. Based on end user, the market is segmented into hospitals, long term care facilities and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Monoclonal Antibody Therapy Market

The advancement of biotechnology and genetic engineering has significantly propelled the growth of monoclonal antibody therapies. Innovations in these fields have enabled the creation of antibodies that boast enhanced specificity, improved efficacy, and minimized side effects. With the application of genetic manipulation techniques, researchers are able to tailor monoclonal antibodies to effectively target specific diseases, thereby amplifying their therapeutic potential. This progress has not only expanded the possible uses for monoclonal antibody therapies but has also contributed to higher success rates in treatment outcomes, reinforcing the role of these therapies in modern medicine.

Restraints in the Monoclonal Antibody Therapy Market

Monoclonal antibody therapies, while beneficial, are not without their challenges, as they can lead to various side effects and safety issues. Patients may experience infusion-related reactions upon receiving the treatment, which can range from mild to severe. Additionally, there is the risk of immunogenicity, where the immune system reacts negatively to the therapy. Off-target effects may also arise, resulting in unintended interactions within the body. To safeguard patient safety and uphold trust in these therapies, it is essential to conduct thorough monitoring, implement strong safety assessments, and communicate potential risks clearly. Effectively managing these concerns is critical for ensuring patient well-being and complying with regulatory requirements.

Market Trends of the Monoclonal Antibody Therapy Market

The monoclonal antibody therapy market is experiencing a notable shift towards increasing adoption and development of personalized and targeted therapies. This trend is driven by the integration of advanced diagnostics, genetic profiling, and biomarker identification, enabling healthcare providers to customize treatments for individual patients. Such strategic personalization enhances therapeutic efficacy while minimizing adverse effects, thereby improving overall treatment outcomes for diseases like cancer, autoimmune disorders, and infectious diseases. As the healthcare landscape evolves, the demand for monoclonal antibodies that align with personalized medicine principles continues to grow, fueling innovation and reshaping treatment paradigms in the biopharmaceutical industry.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Monoclonal Antibody Therapy Market Size by Production & CAGR (2026-2033)

• Market Overview
• In Vitro
• In Vivo

Global Monoclonal Antibody Therapy Market Size by Source & CAGR (2026-2033)

• Market Overview
• Human
• Humanized
• Chimeric
• Other

Global Monoclonal Antibody Therapy Market Size by Therapy & CAGR (2026-2033)

• Market Overview
• Autoimmune And Inflammatory Disorders
• Oncology
• Hematology
• Ophthalmology
• Others

Global Monoclonal Antibody Therapy Market Size by Administration & CAGR (2026-2033)

• Market Overview
• Intravenous
• Subcutaneous
• Other

Global Monoclonal Antibody Therapy Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Long Term Care Facilities
• Others
• Global Monoclonal Antibody Therapy Market Size & CAGR (2026-2033)
• North America (Production, Source, Therapy, Administration, End User)
  • US
  • Canada
• Europe (Production, Source, Therapy, Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Production, Source, Therapy, Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Production, Source, Therapy, Administration, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Production, Source, Therapy, Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
• Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Zoetis Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Elanco Animal Health Incorporated (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ceva Sante Animale (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virbac (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetoquinol (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intervet Inc. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alltech (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Huvepharma (Bulgaria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kemin Industries (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novus International (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biomin Holding GmbH (Austria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ADM Animal Nutrition (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adisseo (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DSM (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations